CureVac N.V. (CVAC) Company Profile & Statistics

CureVac N.V.
CVAC
(Nasdaq - US)
N/A
2.52
+0.00 (0.00%)
in:usd•As of: Apr 30, 2024 15:59 UTC -4
Open
2.47
High
2.62
Low
2.47

About CureVac N.V.

CEO

Franz-Werner Haas

Headquarters

friedrich-miescher-strasse 15

t¿bingen, 2m 72076, germany

Auditor

Ernst & Young GmbH

Employees

455

Share Holders

N/A

Website

www.curevac.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.

CureVac N.V. Statistics

Valuation Measures

Market Capitalization ²	564.18M
Enterprise Value	173.87M
Enterprise Value/EBITDA (ttm)	-0.64
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.93
Price to Sales (ttm)	8.97
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	-119.47%
Operating Margin (ttm)	-483.85%
Profit Margin (ttm)	-497.56%
Return on Equity (ttm)	-41.87%
Return on Invested Capital (ttm)	-25.13%
Return on Assets (ttm)	-29.65%

Income Statement

Revenue (ttm)	58.18M
Revenue Per Share (ttm)	N/A
Gross Profit (ttm)	-76.42M
EBITDA (ttm)³	-271.46M
Net Income Avi to Common (ttm)	-281.58M
Diluted EPS (ttm)	N/A

Share Statistics

Beta (5Y Monthly)	2.51
52-Week Change	-64.00%
S&P500 52-Week Change	24.15%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	N/A
Dividend Yield	0.00%
Float ⁴	0.00
% Held by Insiders	N/A
% Held by Institutions	17.26%

Balance Sheet

Total Cash (mrq)	438.45M
Total Cash Per Share (mrq)	N/A
Total Debt (mrq)	45.27M
Total Debt/Equity (mrq)	6.99%
Current Ratio (mrq)	3.56%
Quick Ratio (mrq)	2.43%
Book Value Per Share (mrq)	2.93

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.09
Free Cash Flow (ytd)	-285.66M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CureVac N.V.

Trade With A Regulated Broker